Kerendia (finerenone) / Bayer - LARVOL DELTA

Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome. (PubMed, Int J Mol Sci) - "Management requires a multimodal approach tailored to the patient's lipid phenotype and overall cardiovascular risk, incorporating a range of lipid-lowering strategies including statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, icosapent ethyl, and emerging therapies targeting apoC-III, ANGPTL3, and Lp(a). Beyond lipid lowering, lifestyle interventions and cardiometabolic therapies such as glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and finerenone may provide complementary cardiometabolic and renal protection."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • ANGPTL3 • APOB

Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies. (PubMed, J Clin Med) - "Obesity-related chronic kidney disease (ob-CKD) is an increasingly prevalent condition whose pathogenesis extends beyond excess body mass to the metabolic dysfunction of visceral adipose tissue (VAT)...The therapeutic landscape now includes agents with combined weight-loss and nephroprotective properties: glucagon-like peptide-1 (GLP-1) receptor agonists (FLOW trial), dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists (tirzepatide), sodium-glucose co-transporter 2 inhibitors (SGLT2i), and non-steroidal mineralocorticoid receptor antagonists (finerenone), alongside metabolic surgery for refractory cases. This review provides an integrative framework for shifting clinical practice from BMI-centric to visceral adiposity-driven approaches in the prevention and management of ob-CKD."

Journal • Review • Chronic Kidney Disease • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Oncology • Renal Disease • IL6 • LEP • TNFA

Association of finerenone with graded proteinuria improvement in type 2 diabetes with chronic kidney disease and proteinuria >1 g/d: a retrospective cohort study. (PubMed, Front Endocrinol (Lausanne)) - "MMRM analysis revealed a greater reduction in 24h-UTP in the finerenone group, while eGFR and serum potassium changes did not differ significantly between groups. In patients with T2DM and proteinuria >1 g/d, finerenone increased the probability of sustained graded proteinuria improvement, shortened the time to improvement, and was not associated with a significantly increased risk of hyperkalemia over 12 months, although the interpretation of safety findings is limited by baseline differences in kidney function and concomitant medication use between groups."

Journal • Retrospective data • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

FINE-IMSS-MX: A Study to Learn More About How Well Finerenone Works in Real-World in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social) (clinicaltrials.gov) - P=N/A | N=800 | Not yet recruiting | Sponsor: Bayer

New trial • Real-world evidence • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure. (PubMed, JACC Adv) - "The nonsteroidal MRA finerenone has demonstrated efficacy in this population and was approved for treatment in July 2025 by the U.S. Food and Drug Administration...Guideline recommendations and HF label indications are discussed, highlighting practical considerations for the safe use of MRAs in clinical practice. In addition, the therapeutic management of patients with HFmrEF/HFpEF and concomitant cardiovascular, kidney, and metabolic diseases is considered."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders

Finerenone Regulates Macrophage-Tubular Crosstalk in Diabetic Nephropathy via the AMPK/PKM2 Pathway. (PubMed, Ann Clin Lab Sci) - "FIN ameliorates DN by regulating the AMPK/PKM2 pathway to influence macrophage polarization and attenuate RTEC injury."

Journal • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • KIM1 • PKM

Finerenone for Patients With Primary Aldosteronism (FAIRY) (clinicaltrials.gov) - P4 | N=306 | Completed | Sponsor: Chongqing Medical University | Recruiting ➔ Completed | Trial primary completion date: Jun 2025 ➔ Apr 2026

Trial completion • Trial primary completion date • Endocrine Disorders

Efficacy of finerenone and/or roflumilast in alleviation of intestinal ischemic reperfusion injury via regulation of IL10/AMPK/VEGF/eNOS pathway in rats. (PubMed, Iran J Basic Med Sci) - "FIN/ROF could mitigate IIR-induced hepatic and intestinal damage via FIN-mediated blockade of mineralocorticoid receptors and ROF-mediated inhibition of phosphodiesterase 4, and through antioxidant, anti-apoptotic, and anti-inflammatory properties with regulation of the IL-10/AMPK/VEGF/eNOS pathway. Thus, FIN/ROF is a potential medical treatment for IIR, in addition to surgery."

Journal • Preclinical • Cardiovascular • Liver Failure • Oncology • Reperfusion Injury • CASP3 • IL10 • NOS3 • TNFA

Integrated proteomic-transcriptomic profiling identifies NR3C2 up-regulation and a candidate plasma-protein-handling signature in chronic podocyte injury. (PubMed, FEBS J) - "Being the pharmacological target of finerenone, NR3C2 represents a clinically relevant protein-level change that transcriptomic profiling alone would miss...Complement C5 was one prominent member of this candidate plasma-protein-handling signature. Together, these findings show that the late phase of podocyte-driven CKD involves distributed protein-level remodelling, including an RNA-discordant increase in NR3C2 protein and a candidate plasma-protein-handling signature."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Finerenone vs Spironolactone in MASH-Cirrhosis With CKD: A Propensity Score-Matched Real-World Study (ACG 2026) - "1:1 propensity score matching on demographics, heart failure, portal hypertension, varices, medications (ARBs, ACEi, furosemide, beta-blockers), and labs (potassium, bilirubin, eGFR, platelets, albumin, ALT, INR). Before matching, 207â227 finerenone and 26,400â29,701 spironolactone users were identified. Finerenone users had lower bilirubin (0.81 vs 2.21 mg/dL), higher albumin (3.89 vs 3.24 g/dL), and lower baseline eGFR (52.5 vs 71.9 mL/min/1.73m²). After PSM, 203, 224, and 210 pairs were analyzed at 1, 3, and 5 years."

Clinical • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetic Nephropathy • Fibrosis • Heart Failure • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Portal Hypertension • Renal Disease

A comparative real-world analysis of finerenone and steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. (PubMed, Front Pharmacol) - "In this real-world cohort, finerenone and sMRAs showed comparable antiproteinuric effectiveness. sMRAs were associated with a more pronounced blood pressure reduction, whereas finerenone showed more favorable renal profile, with lower treatment discontinuation and side effects."

Journal • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Ovarian fibrosis as a common mechanism of infertility. (PubMed, Biol Reprod) - "Further, in early human trials, antifibrotic finerenone yields mature oocytes and embryos in women with premature ovarian insufficiency. While the current focus in standard infertility treatment aims to improve follicle and hormone health, fibrosis may be reversible and preventable, making it a candidate therapeutic target that could complement existing treatments. However, key gaps remain: no standardized measure of ovarian fibrosis, uncertain rodent-to-human translation, and no study linking fibrosis measurement to a fertility outcome in human patients."

Journal • Endometriosis • Fibrosis • Genetic Disorders • Gynecology • Immunology • Infertility • Inflammation • Obesity • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders • Women's Health

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States (clinicaltrials.gov) - P=N/A | N=238038 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed | N=150000 ➔ 238038

Enrollment change • Trial completion • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors. (PubMed, Handb Exp Pharmacol) - "The chapter also reviews emerging data on combination strategies with GLP-1 receptor agonists or finerenone, long-term treatment considerations, and projections suggesting substantial delays in kidney failure with earlier initiation. Collectively, these data support broad implementation of SGLT2i as core disease-modifying therapy in CKD, while highlighting priority areas for future research in underrepresented populations and optimized combination regimens."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Twenty-Four-Week UACR Response Trajectories and Clinical Correlates of Residual Albuminuria in Diabetic Kidney Disease During Finerenone Therapy: A Real-World Longitudinal Study. (PubMed, Diabetes Metab Syndr Obes) - "Patients with DKD and residual albuminuria during finerenone therapy showed distinct 24-week UACR response trajectories. Trajectory analysis provides exploratory real-world evidence for dynamic risk stratification, but the identified patterns and clinical correlates require validation in larger, prospective, multicenter cohorts with longer follow-up."

Journal • Observational data • Real-world evidence • Diabetic Nephropathy • Nephrology • Renal Disease

Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial. (PubMed, JAMA Cardiol) - No abstract available

Clinical • Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

Non-albumin proteinuria as a candidate biomarker of treatment response to finerenone in diabetic kidney disease: a real-world cohort study. (PubMed, Front Endocrinol (Lausanne)) - "Finerenone treatment was associated with a reduction in NAP, particularly among patients with higher baseline proteinuria, suggesting a possible effect on tubulointerstitial injury-related processes beyond albuminuria reduction. Prospective multicenter studies are needed to validate uNAPCR as a treatment-response biomarker against clinical endpoints."

Biomarker • Journal • Real-world evidence • Retrospective data • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Finerenone and Cardiac Remodeling in HFpEF (clinicaltrials.gov) - P4 | N=194 | Not yet recruiting | Sponsor: Assiut University

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. (PubMed, CEN Case Rep) - "Notably, his proteinuria improved following discontinuation of durvalumab and treatment with losartan potassium, dapagliflozin, and finerenone, without a substantial increase in the glucocorticoid dose. The clinical course highlights the heterogeneity of durvalumab-associated nephrotic syndrome."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Infectious Disease • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Sarfez Pharmaceuticals, Inc. | N=30 ➔ 0 | Initiation date: Dec 2025 ➔ May 2025 | Recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Serum Potassium and Mineralocorticoid Receptor Antagonists As Modifiers of Atrial Arrhythmia Recurrence After Catheter Ablation for Atrial Fibrillation: A Narrative Review With Systematic Search and Mechanistic Synthesis. (PubMed, Cureus) - "We aimed to synthesize the clinical and mechanistic evidence on whether serum potassium, potassium-management strategies, and MRA therapy (steroidal: spironolactone, eplerenone; nonsteroidal: esaxerenone, finerenone) modify recurrence, and to derive a testable mechanistic framework. Current evidence supports avoiding hypokalemia and hyperkalemia, correcting reversible disturbances, and prescribing MRAs for established indications with appropriate monitoring; it does not justify routine potassium supplementation or MRA use solely to prevent post-ablation recurrence. Prospective, adequately powered randomized studies with longitudinal potassium assessment and rigorous rhythm monitoring are required before mechanism-based post-ablation interventions can be recommended."

Journal • Review • Atrial Fibrillation • Cardiovascular • Immunology

Rapid Effects of Finerenone on Pulmonary and Venous Hemodynamics in Rabbits after Its Intravenous Administration in Experiment. (PubMed, Bull Exp Biol Med) - "Concurrently, blood flow in the caudal vena cava increased to a greater extent than after nifedipine administration. The increased cranial and caudal vena cava flows after intravenous injection of finerenone were a result of vasodilatation of arterial vessels in the respective regions."

Journal • Preclinical

Fragility metrics are the wrong tool for finerenone's cardiovascular evidence. (PubMed, Eur J Heart Fail) - No abstract available

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Finerenone for Premature Ovarian Insufficiency (POI) (clinicaltrials.gov) - P2 | N=46 | Not yet recruiting | Sponsor: The University of Hong Kong-Shenzhen Hospital

New P2 trial • Women's Health

FINESSE-CKD: Optimizing Albuminuria Treatment in CKD With Finerenone and Semaglutide (clinicaltrials.gov) - P2 | N=41 | Completed | Sponsor: University Medical Center Groningen

New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease